{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:47:31Z","timestamp":1792799251685,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovation Fund for Outstanding Doctoral Students of Peking University Health Science Center","award":["22115131"],"award-info":[{"award-number":["22115131"]}]},{"name":"Peking University Medicine Sailing Program for Young Scholars\u2019 Scientific & Technological Innovation","award":["BMU2025YFJHPY039"],"award-info":[{"award-number":["BMU2025YFJHPY039"]}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2024-1-1021"],"award-info":[{"award-number":["2024-1-1021"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["92459302, 82203881, U22A20327"],"award-info":[{"award-number":["92459302, 82203881, U22A20327"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Science and Technology Plan","award":["Z231100007423009"],"award-info":[{"award-number":["Z231100007423009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02577-x","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:05:14Z","timestamp":1770696314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Haoxin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"9","key":"2577_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrc3559","volume":"13","author":"N Tebbutt","year":"2013","unstructured":"Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13(9):663\u201373.","journal-title":"Nat Rev Cancer"},{"key":"2577_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070903","author":"X Cheng","year":"2024","unstructured":"Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes. 2024. https:\/\/doi.org\/10.3390\/genes15070903.","journal-title":"Genes"},{"issue":"9742","key":"2577_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"6","key":"2577_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/ajcp\/aqw206","volume":"146","author":"AN Bartley","year":"2016","unstructured":"Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American Pathologists, American society for clinical Pathology, and American society of clinical oncology. Am J Clin Pathol. 2016;146(6):647\u201369.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2577_CR5","first-page":"239","volume":"26","author":"WH Kim","year":"2018","unstructured":"Kim WH, Gomez-Izquierdo L, Vilardell F, Chu KM, Soucy G, Dos Santos LV, et al. HER2 status in gastric and gastroesophageal junction cancer: results of the Large, multinational HER-EAGLE Study. Applied immunohistochemistry & molecular morphology. AIMM. 2018;26(4):239\u201345.","journal-title":"AIMM"},{"issue":"19","key":"2577_CR6","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","volume":"22","author":"LF Abrahao-Machado","year":"2016","unstructured":"Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22(19):4619\u201325.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2577_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from toga: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476\u201384.","journal-title":"Gastric Cancer"},{"issue":"7","key":"2577_CR8","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab Deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933\u201342.","journal-title":"Nat Med"},{"issue":"25","key":"2577_CR9","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"11","key":"2577_CR10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","volume":"41","author":"Z Peng","year":"2021","unstructured":"Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173\u201382.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"2577_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab Deruxtecan in Anti-Human epidermal growth factor receptor 2 Treatment-Naive patients with human epidermal growth factor receptor 2-Low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023;41(4):816\u201325.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2577_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5230\/jgc.2025.25.e3","volume":"25","author":"HS Lee","year":"2025","unstructured":"Lee HS. Spatial and temporal tumor heterogeneity in gastric cancer: discordance of predictive biomarkers. J Gastric Cancer. 2025;25(1):192\u2013209.","journal-title":"J Gastric Cancer"},{"issue":"1","key":"2577_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pathol.2018.09.057","volume":"51","author":"J Cho","year":"2018","unstructured":"Cho J, Kang SY, Kim K-M. MMR protein immunohistochemistry and microsatellite instability in gastric cancers. Pathology. 2018;51(1):110\u20133.","journal-title":"Pathology"},{"issue":"10","key":"2577_CR14","doi-asserted-by":"publisher","first-page":"e70054","DOI":"10.1002\/ctm2.70054","volume":"14","author":"H Peng","year":"2024","unstructured":"Peng H, Jiang L, Yuan J, Wu X, Chen N, Liu D, et al. Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis. Clin Transl Med. 2024;14(10):e70054.","journal-title":"Clin Transl Med"},{"issue":"1","key":"2577_CR15","doi-asserted-by":"publisher","first-page":"e1155","DOI":"10.1002\/ctm2.1155","volume":"13","author":"H Peng","year":"2023","unstructured":"Peng H, Wu X, Liu S, He M, Xie C, Zhong R, et al. Multiplex Immunofluorescence and single-cell transcriptomic profiling reveal the Spatial cell interaction networks in the non-small cell lung cancer microenvironment. Clin Transl Med. 2023;13(1):e1155.","journal-title":"Clin Transl Med"},{"key":"2577_CR16","doi-asserted-by":"publisher","first-page":"112931","DOI":"10.1016\/j.ejca.2023.05.019","volume":"189","author":"K Jia","year":"2023","unstructured":"Jia K, Chen Y, Xie Y, Chong X, Li Y, Wu Y, et al. Multidimensional immune profiling in gastric cancer multiplex immunohistochemistry atlas from Peking university cancer hospital project informs PD-1\/PD-L1 Blockade efficacy. Eur J Cancer. 2023;189:112931.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2577_CR17","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Jia K, Sun Y, Zhang C, Li Y, Zhang L, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022;13(1):4851.","journal-title":"Nat Commun"},{"issue":"3","key":"2577_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al. Single-Cell atlas of lineage States, tumor Microenvironment, and Subtype-Specific expression programs in gastric cancer. Cancer Discov. 2022;12(3):670\u201391.","journal-title":"Cancer Discov"},{"key":"2577_CR19","doi-asserted-by":"crossref","unstructured":"Isnan S, Bin Abdullah AF, Shariff AR, Ishak I, Syed Ismail SN, Appanan MR. Moran\u2019s I and Geary\u2019s C: investigation of the effects of spatial weight matrices for assessing the distribution of infectious diseases. Geospat Health. 2025;20(1).","DOI":"10.4081\/gh.2025.1277"},{"issue":"19","key":"2577_CR20","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/bioinformatics\/btx351","volume":"33","author":"C Schmal","year":"2017","unstructured":"Schmal C, Myung J, Herzel H, Bordyugov G. Moran\u2019s i quantifies spatio-temporal pattern formation in neural imaging data. Bioinformatics. 2017;33(19):3072\u20139.","journal-title":"Bioinformatics"},{"key":"2577_CR21","first-page":"361","volume":"13","author":"M Koubay do Amaral","year":"2015","unstructured":"Koubay do Amaral M, Netto S, Lingnau C, Filho A. Evaluation of the Morisita index for determination of the spatial distribution of species in a fragment of araucaria forest. Appl Ecol Environ Res. 2015;13:361\u201372.","journal-title":"Appl Ecol Environ Res"},{"issue":"6","key":"2577_CR22","first-page":"252","volume":"11","author":"M Morisita","year":"1961","unstructured":"Morisita M. Measuring of dispersion of individuals and analysis of the distributional patterns. Jpn J Ecol. 1961;11(6):252.","journal-title":"Jpn J Ecol"},{"key":"2577_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1590\/S0103-84782011005000037","volume":"41","author":"J Scalon","year":"2011","unstructured":"Scalon J, Avelar M, Alves G, Zacarias M. Spatial and temporal dynamics of coffee-leaf-miner and predatory wasps in organic coffee field in formation. Cienc Rural. 2011;41:646\u201352.","journal-title":"Cienc Rural"},{"issue":"9","key":"2577_CR24","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.21037\/tlcr-22-629","volume":"11","author":"Y Wang","year":"2022","unstructured":"Wang Y, Peng L, Zhao M, Xiong Y, Xue J, Li B, et al. Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer. Transl Lung Cancer Res. 2022;11(9):1936\u201350.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2577_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13058-015-0638-4","volume":"17","author":"CC Maley","year":"2015","unstructured":"Maley CC, Koelble K, Natrajan R, Aktipis A, Yuan Y. An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. Breast Cancer Res. 2015;17(1):131.","journal-title":"Breast Cancer Res"},{"key":"2577_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107382","volume":"165","author":"A Agten","year":"2023","unstructured":"Agten A, Bl\u00e1zquez-Moreno A, Crabbe M, Tuefferd M, Goehlmann H, Geys H, et al. Measures of spatial heterogeneity in the liver tissue micro-environment as predictive factors for fibrosis score. Comput Biol Med. 2023;165:107382.","journal-title":"Comput Biol Med"},{"key":"2577_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.010","author":"Y Goltsev","year":"2018","unstructured":"Goltsev Y, Samusik N, Kennedy-Darling J, Bhate S, Hale M, Vazquez G, et al. Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell. 2018. https:\/\/doi.org\/10.1016\/j.cell.2018.07.010.","journal-title":"Cell"},{"issue":"1","key":"2577_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on immunogenomic profiling. J Exp Clin Cancer Res. 2018;37(1):327.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2577_CR29","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1038\/s41467-020-18546-x","volume":"11","author":"D Xiong","year":"2020","unstructured":"Xiong D, Wang Y, You M. A gene expression signature of TREM2hi macrophages and \u03b3\u03b4 t cells predicts immunotherapy response. Nat Commun. 2020;11(1):5084.","journal-title":"Nat Commun"},{"key":"2577_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000778","author":"EM Garrido-Martin","year":"2020","unstructured":"Garrido-Martin EM, Mellows TWP, Clarke J, Ganesan A-P, Wood O, Cazaly A, et al. M1hot tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000778.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2577_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cell.2008.01.046","volume":"133","author":"D Padua","year":"2008","unstructured":"Padua D, Zhang XHF, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. <article-title update=\"added\">TGF\u03b2 primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66\u201377.","journal-title":"Cell"},{"key":"2577_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.038","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018. https:\/\/doi.org\/10.1016\/j.cell.2018.10.038.","journal-title":"Cell"},{"issue":"11","key":"2577_CR33","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41588-020-00726-6","volume":"52","author":"GS Kinker","year":"2020","unstructured":"Kinker GS, Greenwald AC, Tal R, Orlova Z, Cuoco MS, McFarland JM, et al. Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. Nat Genet. 2020;52(11):1208\u201318.","journal-title":"Nat Genet"},{"issue":"1","key":"2577_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"2577_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert M, Klinger B, Kl\u00fcnemann M, Sieber A, Uhlitz F, Sauer S, et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun. 2018;9(1):20.","journal-title":"Nat Commun"},{"issue":"D1","key":"2577_CR36","doi-asserted-by":"publisher","first-page":"D900","DOI":"10.1093\/nar\/gky939","volume":"47","author":"H Yuan","year":"2019","unstructured":"Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019;47(D1):D900\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2577_CR37","doi-asserted-by":"publisher","first-page":"vbac016","DOI":"10.1093\/bioadv\/vbac016","volume":"2","author":"P Badia-I-Mompel","year":"2022","unstructured":"Badia-I-Mompel P, V\u00e9lez Santiago J, Braunger J, Geiss C, Dimitrov D, M\u00fcller-Dott S, et al. DecoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform Adv. 2022;2(1):vbac016.","journal-title":"Bioinform Adv"},{"issue":"7517","key":"2577_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Comprehensive molecular characterization of gastric adenocarcinoma","year":"2014","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"key":"2577_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-0716-0327-7_17","volume":"2120","author":"J Racle","year":"2020","unstructured":"Racle J, Gfeller D. EPIC: a tool to estimate the proportions of different cell types from bulk gene expression data. Methods Mol Biol. 2020;2120:233\u201348.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2577_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol"},{"issue":"3","key":"2577_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.21147\/j.issn.1000-9604.2024.03.07","volume":"36","author":"Z Li","year":"2024","unstructured":"Li Z, Zhao H, Hu H, Shang H, Ren Y, Qiu W, et al. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer. Chin J Cancer Res. 2024;36(3):306\u201321.","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"2577_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"2","key":"2577_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10555-017-9673-1","volume":"36","author":"MZ Wojtukiewicz","year":"2017","unstructured":"Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn KV. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249\u201362.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2577_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","volume":"35","author":"J Cooper","year":"2019","unstructured":"Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35(3):347\u201367.","journal-title":"Cancer Cell"},{"issue":"12","key":"2577_CR45","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2577_CR46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450\u201365.","journal-title":"Cancer Cell"},{"issue":"5","key":"2577_CR47","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","volume":"51","author":"Z Chen","year":"2019","unstructured":"Chen Z, Ji Z, Ngiow SF, Manne S, Cai Z, Huang AC, et al. TCF-1-Centered transcriptional network drives an effector versus exhausted CD8 T Cell-Fate decision. Immunity. 2019;51(5):840\u2013e555.","journal-title":"Immunity"},{"issue":"1","key":"2577_CR48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2577_CR49","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"6029","key":"2577_CR50","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600\u20133.","journal-title":"Science"},{"issue":"4","key":"2577_CR51","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity. 2015;42(4):607\u201312.","journal-title":"Immunity"},{"issue":"27","key":"2577_CR52","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41388-023-02715-5","volume":"42","author":"H Zhong","year":"2023","unstructured":"Zhong H, Lu W, Tang Y, Wiel C, Wei Y, Cao J, et al. SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity. Oncogene. 2023;42(27):2183\u201394.","journal-title":"Oncogene"},{"key":"2577_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100794","author":"A Kula","year":"2024","unstructured":"Kula A, Koszewska D, Kot A, Dawidowicz M, Mielcarska S, Waniczek D, et al. The importance of HHLA2 in solid tumors-a review of the literature. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13100794.","journal-title":"Cells"},{"key":"2577_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.10.004","volume":"97","author":"X Wang","year":"2023","unstructured":"Wang X, Eichhorn PJA, Thiery JP. TGF-\u03b2, emt, and resistance to anti-cancer treatment. Semin Cancer Biol. 2023;97:1\u201311.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2577_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21(1):104.","journal-title":"Mol Cancer"},{"issue":"23","key":"2577_CR56","doi-asserted-by":"publisher","first-page":"20399","DOI":"10.1074\/jbc.M200206200","volume":"277","author":"J Czuwara-Ladykowska","year":"2002","unstructured":"Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem. 2002;277(23):20399\u2013408.","journal-title":"J Biol Chem"},{"issue":"3","key":"2577_CR57","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"key":"2577_CR58","doi-asserted-by":"crossref","unstructured":"Garner H, Martinovic M, Liu NQ, Bakker NAM, Velilla IQ, Hau CS et al. Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread. Cancer Cell. 2025;43(7):1279-95.e9.","DOI":"10.1016\/j.ccell.2025.04.007"},{"key":"2577_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202507167","author":"S Liu","year":"2025","unstructured":"Liu S, Zhou Y, Li G, Zhu B, Wu F, Zhou J, et al. PLAUR(+) neutrophils drive anti-PD-1 therapy resistance in patients with hepatocellular carcinoma by shaping an immunosuppressive microenvironment. Adv Sci. 2025. https:\/\/doi.org\/10.1002\/advs.202507167.","journal-title":"Adv Sci"},{"issue":"4","key":"2577_CR60","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10120-014-0430-7","volume":"18","author":"Y Kurokawa","year":"2015","unstructured":"Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18(4):691\u20137.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2577_CR61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-024-02085-w","volume":"23","author":"Y Chen","year":"2024","unstructured":"Chen Y, Jia K, Chong X, Xie Y, Jiang L, Peng H, et al. Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer. Mol Cancer. 2024;23(1):169.","journal-title":"Mol Cancer"},{"issue":"12","key":"2577_CR62","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1038\/s41591-025-04022-w","volume":"31","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Oh D-Y, Pelster M, Wainberg ZA, Prusty S, Nelson S, et al. Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial. Nat Med. 2025;31(12):4274\u201380.","journal-title":"Nat Med"},{"key":"2577_CR63","doi-asserted-by":"publisher","first-page":"580045","DOI":"10.3389\/fonc.2020.580045","volume":"10","author":"H Lv","year":"2020","unstructured":"Lv H, Zhang J, Sun K, Nie C, Chen B, Wang J, et al. Expression of human epidermal growth factor Receptor-2 status and programmed cell death Protein-1 ligand is associated with prognosis in gastric cancer. Front Oncol. 2020;10:580045.","journal-title":"Front Oncol"},{"issue":"8","key":"2577_CR64","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","volume":"21","author":"S Wu","year":"2019","unstructured":"Wu S, Zhang Q, Zhang F, Meng F, Liu S, Zhou R, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat Cell Biol. 2019;21(8):1027\u201340.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2577_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02195-x","volume":"10","author":"D Liu","year":"2025","unstructured":"Liu D, Gong J, Li J, Qi C, Niu Z, Liu B, et al. Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4\/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study. Signal Transduct Target Ther. 2025;10(1):104.","journal-title":"Signal Transduct Target Ther"},{"key":"2577_CR66","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1200\/JCO.2024.42.16_suppl.2504","volume":"42","author":"J Gong","year":"2024","unstructured":"Gong J, Liu C, Yao J, Xue J, Dai J, Markman B, et al. Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: results from phase 1\/2 studies. J Clin Oncol. 2024;42:2504.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2577_CR67","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh D-Y. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024;21(9):675\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"key":"2577_CR68","doi-asserted-by":"publisher","first-page":"S869","DOI":"10.1016\/j.annonc.2023.09.1463","volume":"34","author":"CK Lee","year":"2023","unstructured":"Lee CK, Park S, Che J, Kwon WS, Rha SY. 1551P clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer. Ann Oncol. 2023;34:S869.","journal-title":"Ann Oncol"},{"issue":"6","key":"2577_CR69","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287\u201395.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2577_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01487-5","volume":"16","author":"M Niu","year":"2023","unstructured":"Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, et al. Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023;16(1):94.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2577_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/imm3.70007","volume":"1","author":"L Chen","year":"2025","unstructured":"Chen L, Lin A, Tang B, Li K, Qian Y, Liu X, et al. The future of cancer therapy: nanomaterials and tumor microenvironment. iMetaMed. 2025;1(1):e70007.","journal-title":"iMetaMed"},{"key":"2577_CR72","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhang S, Liu K, Hu X, Gu X. Advances in drug discovery based on network pharmacology and omics technology. Curr Pharm Anal. 2024;21(1):33\u201343.","DOI":"10.1016\/j.cpan.2024.12.002"},{"issue":"7","key":"2577_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06873-6","volume":"15","author":"G Zhu","year":"2024","unstructured":"Zhu G, Wang Y, Wang Y, Huang H, Li B, Chen P, et al. Myofibroblasts derived type V collagen promoting tissue mechanical stress and facilitating metastasis and therapy resistance of lung adenocarcinoma cells. Cell Death Dis. 2024;15(7):493.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2577_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.scib.2024.11.012","volume":"70","author":"X Song","year":"2025","unstructured":"Song X, Li Z, Wang X, Du H, Jia Y, Chen S, et al. SLC40A1\u2009+\u2009macrophages contribute to the immunosuppressive tumor microenvironment in EGFR-mutated lung cancer. Sci Bull. 2025;70(1):47\u201350.","journal-title":"Sci Bull"},{"issue":"8","key":"2577_CR75","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","volume":"39","author":"C Garlanda","year":"2021","unstructured":"Garlanda C, Mantovani A. Interleukin-1 in tumor progression, therapy, and prevention. Cancer Cell. 2021;39(8):1023\u20137.","journal-title":"Cancer Cell"},{"issue":"25","key":"2577_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202417593","volume":"12","author":"D Zeng","year":"2025","unstructured":"Zeng D, Yu Y, Qiu W, Ou Q, Mao Q, Jiang L, et al. Immunotyping the tumor microenvironment reveals molecular heterogeneity for personalized immunotherapy in cancer. Adv Sci. 2025;12(25):e2417593.","journal-title":"Adv Sci"},{"issue":"22","key":"2577_CR77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00748","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara K, Lorenzen S, Li J, Bai Y, Fern\u00e1ndez MG, Aguilar M, et al. Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced metastatic gastroesophageal adenocarcinoma: the phase III, randomized LEAP-015 study. J Clin Oncol. 2025;43(22):JCO2500748.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2577_CR78","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s12885-019-5687-0","volume":"19","author":"EA Perez","year":"2019","unstructured":"Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im Y-H, et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine\u2009\u00b1\u2009pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer. 2019;19(1):517.","journal-title":"BMC Cancer"},{"issue":"1","key":"2577_CR79","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F-H Wang","year":"2023","unstructured":"Wang F-H, Zhang X-T, Tang L, Wu Q, Cai M-Y, Li Y-F, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond). 2023;44(1):127\u201372.","journal-title":"Cancer Commun (Lond)"},{"key":"2577_CR80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"issue":"2","key":"2577_CR81","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10549-023-07079-8","volume":"202","author":"Z Chen","year":"2023","unstructured":"Chen Z, Jia H, Zhang H, Chen L, Zhao P, Zhao J, et al. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023;202(2):313\u201323.","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"2577_CR82","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"2577_CR83","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","volume":"24","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, et al. Phase I study of the Recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24(4):913\u201325.","journal-title":"Gastric Cancer"},{"key":"2577_CR84","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, et al. Disitamab Vedotin (RC48) plus Toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024;68:102415.","journal-title":"EClinicalMedicine"},{"issue":"17suppl","key":"2577_CR85","first-page":"LBA4012","volume":"43","author":"L Shen","year":"2025","unstructured":"Shen L, Peng Z, Li C, Lu L, Wang X, Zhang J, et al. Disitamab Vedotin (DV) plus Toripalimab (Tor) and chemotherapy (C)\/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la\/m). Gastric Cancer. 2025;43(17suppl):LBA4012\u2013LBA.","journal-title":"Gastric Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02577-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02577-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02577-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:03:05Z","timestamp":1774522985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02577-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2577"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02577-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent of included patients was gained, and this research was approved by the Ethics Committee of Peking University Cancer Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}